Can stem cell therapy help manage stiff-person syndrome?

Question

Hello doctor,

I was diagnosed with stiff-person syndrome (SPS), and despite using muscle relaxants and immunotherapy, my symptoms continue to worsen. I have heard that stem cell therapy might help regulate the autoimmune response and improve muscle control. Are there any studies on stem cell therapy for rare neurological conditions like SPS? Which type of stem cells would be most effective in modulating the immune system and restoring neuromuscular function? How risky is the procedure, and how long does it typically take to see results?

Please advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

Stem cell therapy for stiff-person syndrome (SPS) is still experimental, but there is growing interest in its potential to modulate the immune system and improve muscle control. Since SPS is an autoimmune neurological disorder, stem cell treatments focus on resetting the immune system and reducing the autoantibodies that attack GAD (glutamic acid decarboxylase), a key enzyme in nerve function.

Current research on stem cell therapy for SPS:

Most studies on stem cell therapy for autoimmune diseases (such as multiple sclerosis and myasthenia gravis) involve autologous hematopoietic stem cell transplantation (AHSCT), where the patient's own stem cells are used after chemotherapy to wipe out the dysfunctional immune system.
Some case reports suggest that AHSCT may improve symptoms in SPS, but large clinical trials are lacking.
Mesenchymal stem cells (MSCs) (from bone marrow or umbilical cord) are being studied for their anti-inflammatory effects, but their role in SPS is unclear.

Types of stem cells being investigated for SPS:

Autologous hematopoietic stem cells (AHSCT): Used to reboot the immune system by wiping out autoantibodies attacking GAD. It has shown success in other autoimmune neurologic diseases like MS. It requires high-dose chemotherapy, making it riskier but potentially more effective for severe SPS cases.
Mesenchymal stem cells (MSCs): Have anti-inflammatory and neuroprotective properties. Lower risk than AHSCT but may require multiple infusions over time. Not yet proven for SPS but used experimentally in other neurological autoimmune diseases.

Potential risks and timeline for results:

AHSCT risks: High, due to chemotherapy-related complications like infections, organ toxicity, and graft failure. Recovery can take months to a year.
MSC risks: Lower, but potential risks include immune rejection or lack of long-term effect. Results may take weeks to months and may require repeated infusions.

Both approaches are experimental, and clinical trials are limited.

What does this mean for you?

If your SPS is severe and progressing despite treatment, AHSCT may be an option if you qualify for a trial or specialized center.
MSC therapy is still being studied but may be less risky if available.
Consider discussing immunotherapy combinations (like Rituximab or intravenous immunoglobulin) with your doctor before pursuing stem cell treatment.

I hope this helps you.

Thank you for using iCliniq. Have a great day!